期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
含硼替佐米的不同化疗方案治疗多发性骨髓瘤的临床效果及对患者生存期的影响
1
作者 孙培娟 任蒙蒙 +1 位作者 邢伟 贾冰冰 《医药论坛杂志》 2024年第2期199-202,共4页
目的对含硼替佐米不同化疗方式治疗多发性骨髓瘤(Multiple myeloma,MM)患者的临床效果与生存期影响进行分析。方法选取2020年1月—2023年1月在郑州大学第一附属医院进行治疗的90例MM患者作研究对象,按治疗采用药物不同,将使用硼替佐米+... 目的对含硼替佐米不同化疗方式治疗多发性骨髓瘤(Multiple myeloma,MM)患者的临床效果与生存期影响进行分析。方法选取2020年1月—2023年1月在郑州大学第一附属医院进行治疗的90例MM患者作研究对象,按治疗采用药物不同,将使用硼替佐米+环磷酰胺+地塞米松进行治疗的45例作为对照组,使用硼替佐米+来那度胺+地塞米松进行治疗的45例作为观察组,对比两组患者治疗结果(骨代谢指标、生存期、治疗有效率及不良反应发生情况)。结果观察组患者骨代谢指标(血清钙与核因子κB受体活化因子配体)水平明显优于对照组,差异具有统计学意义(P<0.05)。观察组生存期长于对照组,差异具有统计学意义,P<0.05。观察组治疗有效率82.22%,对照组60.00%,两组数据差异有统计学意义,P<0.05。观察组不良反应情况发生率4.44%,对照组17.78%,组间数据差异有统计学意义,P<0.05。结论给MM患者使用含硼替佐米不同化疗方式进行治疗,对改善其基本症状有一定效果,其中,与硼替佐米+环磷酰胺+地塞米松相比较,使用硼替佐米+来那度胺+地塞米松的效果更佳,对延长患者生存期有积极作用,建议临床推广使用。 展开更多
关键词 硼替佐米 不同化疗方案 多发性骨髓瘤 临床效果 患者生存期
原文传递
EGFR改变图谱及其潜在的临床意义:综合泛癌分析研究 被引量:1
2
作者 Haijing Liu Bo Zhang Zhifu Sun 《癌症》 SCIE CAS CSCD 2020年第8期335-354,共20页
背景与目的人表皮生长因子受体(human epidermal growth factor receptor,EGFR)是癌基因,是EGFR突变型肺癌精准治疗的主要靶点之一。虽然有许多关于单一肿瘤的报道,但尚无关于EGFR突变、过表达、扩增、DNA甲基化及其在多种不同癌症中并... 背景与目的人表皮生长因子受体(human epidermal growth factor receptor,EGFR)是癌基因,是EGFR突变型肺癌精准治疗的主要靶点之一。虽然有许多关于单一肿瘤的报道,但尚无关于EGFR突变、过表达、扩增、DNA甲基化及其在多种不同癌症中并存的临床相关性的综合分析。本研究旨在深入探讨EGFR改变谱图及其治疗和预后意义,填补该领域空白。方法我们分析了癌症基因组计划(The Cancer Genome Atlas,TCGA)数据库中涉及的32种癌症类型、11,314例患者的EGFR基因改变(突变和扩增/缺失)、异常表达和DNA甲基化情况。比较了不同肿瘤类型间的突变频率、基因组位置分布、功能影响和临床靶向治疗的意义,并分析了它们与患者生存期的关系。结果在不同肿瘤中,EGFR改变率、功能域的突变位点、扩增、过表达和DNA甲基化模式均有很大差异。在所有肿瘤中,总体突变率相对较低。多发于肺癌,可靶向治疗的突变主要在Pkinase_Tyr结构域中。改变频率最高的是多形性胶质母细胞瘤,但主要为基因扩增和靶向治疗效果较差的Furin-like结构域内突变。脑低级别胶质瘤通常为EGFR基因扩增和表达增加,且预后不良。虽然结肠和胰腺癌的EGFR突变很少,然而EGFR高表达与患者生存期短显著相关。鳞状细胞癌(无论发生在头颈部、肺部或食管)均表现出相似的特征,改变率为5.0%,以基因扩增为主,EGFR表达增加,且与患者的生存期短相关。在某些癌症中,DNA甲基化与EGFR表达和患者预后密切相关。结论EGFR改变类型、频率、在功能域的分布和表达因癌症类型而异。虽然Pkinase_Tyr结构域突变对于治疗选择更为重要,但扩增或失调引起的表达增加会影响更多类型的肿瘤,并导致预后更差,因此需要对EGFR驱动的肿瘤采取新的治疗策略。 展开更多
关键词 EGFR表达 EGFR突变 表皮生长因子受体 泛癌研究 患者生存期 靶向治疗 癌症基因组计划(The Cancer Genome Atlas TCGA)
下载PDF
Factors associated with the overall survival of elderly patients with hepatocellular carcinoma 被引量:4
3
作者 Hideki Fujii Yoshito Itoh +8 位作者 Naoki Ohnishi Masafumi Sakamoto Tohru Ohkawara Yoshihiko Sawa Koichi Nishida Yasuo Ohkawara Kanji Yamaguchi Masahito Minami Takeshi Okanoue 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第16期1926-1932,共7页
AIM:To identify the factors associated with overall survival of elderly patients with hepatocellular carcinoma(HCC).METHODS:A total of 286 patients with HCC(male/female:178/108,age:46-100 years),who were diagnosed and... AIM:To identify the factors associated with overall survival of elderly patients with hepatocellular carcinoma(HCC).METHODS:A total of 286 patients with HCC(male/female:178/108,age:46-100 years),who were diagnosed and treated by appropriate therapeutic procedures between January 2000 and December 2010,were enrolled in this study.Patients were stratified into two groups on the basis of age:Elderly(≥ 75 years old) and non-elderly(< 75 years old).Baseline clinical characteristics as well as cumulative survival rates were then compared between the two groups.Univariate and multivariate analyses were used to identify the factors associated with prolonged overall survival of patients in each group.Cumulative survival rates in the two groups were calculated separately for each modified Japan Integrated Stage score(mJIS score) category by the Kaplan-Meier method.In addition,we compared the cumulative survival rates of elderly and non-elderly patients with good hepatic reserve capacity(≤ 2 points as per mJIS).RESULTS:In the elderly group,the proportion of female patients,patients with absence of hepatitis B or hepatitis C viral infection,and patients with coexisting extrahepatic comorbid illness was higher(56.8% vs 31.1%,P < 0.001;27.0% vs 16.0%,P = 0.038;33.8% vs 22.2%,P = 0.047;respectively) than that in the nonelderly group.In the non-elderly group,the proportion of hepatitis B virus(HBV)-infected patients was higher than that in the elderly group(9.4% vs 0%,P = 0.006).The cumulative survival rates in the elderly group were 53.7% at 3 years and 32.9% at 5 years,which were equivalent to those in the non-elderly group(55.9% and 39.4%,respectively),as shown by a log-rank test(P = 0.601).In multivariate analysis,prolonged survival was significantly associated with the extent of liver damage and stage(P < 0.001 and P < 0.001,respectively),but was not associated with patient age.However,on individual evaluation of factors in both groups,stage was significantly(P < 0.001) associated with prolonged survival.Regarding mJIS scores of ≤ 2,the rate of female patients with this score was higher in the elderly group when compared to that in the non-elderly group(P = 0.012) and patients ≥ 80 years of age tended to demonstrate shortened survival.CONCLUSION:Survival of elderly HCC patients was associated with liver damage and stage,but not age,except for patients ≥ 80 years with mJIS score ≤ 2. 展开更多
关键词 Age Hepatocellular carcinoma Liver damage STAGE SURVIVAL
下载PDF
内镜下支架安置及针对性护理对食管癌食道狭窄的疗效观察 被引量:2
4
作者 周文玉 《西部医学》 2011年第2期382-383,共2页
目的探讨应用食管支架对食道癌患者生活质量及延长生存期的作用。方法 50例确诊食管狭窄患者纳入研究,安置带膜食管支架并进行针对性护理。结果安置带膜食管支架的患者能有效改善生活质量,平均延长生存期2~18个月。结论安置带膜支架并... 目的探讨应用食管支架对食道癌患者生活质量及延长生存期的作用。方法 50例确诊食管狭窄患者纳入研究,安置带膜食管支架并进行针对性护理。结果安置带膜食管支架的患者能有效改善生活质量,平均延长生存期2~18个月。结论安置带膜支架并进行针对性护理能有效改善食管狭窄患者的生活质量及延长生存期。 展开更多
关键词 带膜食管支架 食管癌 患者生活质量及生存期
下载PDF
Prognostic factors for the survival of 66 cases with extensive stage-small cell lung cancer
5
作者 Heng Cao Yonggui Hong +3 位作者 Shouran Zhao Nengchao Wang Fuyou Zhou Xiaodong Xie 《Oncology and Translational Medicine》 2016年第1期12-15,共4页
Objective The objective of this retrospective study was to investigate the prognostic factors associated with survival among patients with extensive stage-smal cel lung cancer (ES-SCLC). Methods Clinical data from 6... Objective The objective of this retrospective study was to investigate the prognostic factors associated with survival among patients with extensive stage-smal cel lung cancer (ES-SCLC). Methods Clinical data from 66 patients with ES-SCLC diagnosed via histopathology or cytology between July 2005 and July 2009 at Anyang Tumor Hospital (China) were analyzed. Univariate and multivariate Kaplan-Meier, log-rank, and Cox proportional hazard regression analyses were conducted. Results The 12-, 24-, and 36-month survival rates among patients with ES-SCLC were 40.9%, 13.6%, and 6.1%, respectively. The median survival time (MST) was 10 months. Univariate analyses indicated that weight loss, eficacy of first-line chemotherapy, total number of chemotherapy cycles, treatment meth-od, and serum sodium levels significantly influenced survival among patients with ES-SCLC. Multivariate analyses suggested that the eficacy of first-line chemotherapy, total number of chemotherapy cycles, and serum sodium levels were independent prognostic factors associated with survival. Conclusion The eficacy of first-line chemotherapy, total number of chemotherapy cycles, and serum sodium levels are important prognostic factors for patients with ES-SCLC. 展开更多
关键词 extensive stage-small cell lung cancer (ES-SCLC) survival rate PROGNOSIS
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部